Journal
CANCER RESEARCH AND TREATMENT
Volume 53, Issue 1, Pages 87-92Publisher
KOREAN CANCER ASSOCIATION
DOI: 10.4143/crt.2020.741
Keywords
Pemetrexed; Thymidylate synthase; Squamous cell lung cancer
Categories
Funding
- National Cancer Center Research grant [1710230]
Ask authors/readers for more resources
In a single-arm phase II trial, pemetrexed showed modest activity as a salvage chemotherapy in patients with advanced lung SqCC with low TS expression. The toxicity of pemetrexed was generally manageable, with most adverse events being grade 1 or 2.
Purpose Squamous cell carcinomas (SqCC) of the lung often express high levels of thymidylate synthase (TS), which is associated with primary resistance to pemetrexed. We explored the efficacy of pemetrexed in a selected population of patients with lung SqCC with low TS expression. Materials and Methods In this single-arm phase II trial, we enrolled 32 previously-treated patients with advanced lung SqCC exhibiting low immunohistochemical staining for TS (i.e., in 10% or less of tumor cells). The primary endpoint was 12-week progression-free survival (PFS) rate. Results Of 32 patients, eight patients (25%) had an Eastern Cooperative Oncology Group performance status of 2, and seven patients (22%) had previously received three or more lines of chemotherapy. The disease control rate from pemetrexed treatment was 30%, and no objective response was observed. The 12-week PFS rate was 24.5% (95% confidence interval [CI], 13.0 to 46.1). Median PFS was 1.3 months (95% CI, 1.3 to 2.7), and median overall survival was 11.8 months (95% CI, 8.1 to not applicable). Most of adverse events were grade 1 or 2. Conclusion Pemetrexed demonstrated modest activity as a salvage chemotherapy in patients with advanced lung SqCC with low TS expression, although its toxicity was generally manageable.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available